The Global DispatchLA BioMed researcher receives NIH grant to study passive Acinetobacter vaccineThe Global DispatchDr. Spellberg recently received a National Institutes of Health/National Institute of Allergy and Infectious Diseases Grant of $347,474 …
Medscape |
Mechanism for Ipilimumab Pituitary Toxicity Identified
Medscape “An immediate implication for patients is that they can now be tested for the presence of pituitary antibodies to diagnose the presence or predict the development of hypophysitis,” lead author Patrizio Caturegli, MD, from Johns Hopkins University in … |
|
Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are …
PR Newswire (press release) It is expected that these agents will be added to rituximab-containing regimens, such as bendamustine (Teva Pharmaceutical Industries’ Treanda, Mundipharma’s Ribomustin/Levact, Symbio Pharmaceuticals/Eisai’s Treakisym) in combination with rituximab, … |
|
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock …
Wall Street Journal We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, … |
|
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock …
MarketWatch We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, … |
Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 …PharmiWeb.com (press release)MONROVIA Calif. April 10 2014 /PRNewswire/ — Xencor Inc. (NASDAQ: XNCR) a clinical-stage biopharmaceutical company developing engineered monoclonal …
Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 …MarketWatchMONROVIA, Calif., April 10, 2014 /PRNewswire/ — Xencor, Inc. (NASDAQ:XNCR) , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies fo…
BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid …MarketWatchPre-clinical studies show that BL-8040 is efficient, both alone and in combination with anti-cancer drugs such as Rituximab, Imatinib and Bortezomib in lymphoma, C…
BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid …Business Wire (press release)Pre-clinical studies show that BL-8040 is efficient, both alone and in combination with anti-cancer drugs such as Rituximab, Imatinib and Bortezo…
Combination therapy with rituximab may benefit elderly patients with DLBCLHealioIn elderly patients with diffuse large B-cell lymphoma, a combination therapy regimen that includes rituximab appears to yield successful response rates, according to recen…